华兰生物 2024 年第四季度业绩未达预期

March 30, 2025 03:46 PM GMT Hualan Biological Engineering Inc. | Asia Pacific 4Q24 Missed Key Takeaways 4Q24: Revenue and recurring net profit were Rmb4.4bn in 2024 (-18% y/y) and Rmb981mn (-23% y/y), implying 4Q revenue and recurring net profit declines of 38% y/y and 55% y/y. Segment growth: Revenue from plasma grew 11% y/y in 2024, implying 3% decline in 4Q, while vaccines fell 54% y/y in 2024, or -77% y/y decline in 4Q, dragged by price cuts of quadrivalent flu vaccine (-30%) since mid-24 and declined m ...